(1) Monitoring during Tenofovir treatment: During the treatment of Tenofovir, the relevant indicators should be monitored regularly: 1 Biochemical indicators: including liver function indicators such as ALT, should be tested once a month after the start of treatment, 3 consecutive tests, followed by The condition can be improved once every 3 months. 2 Virological markers: HBV DNA was detected once every 3 months after the start of treatment, and HBsAg, HBeAg and anti-HBe were detected once every 3 to 6 months. 3 HCC monitoring: AFP and abdominal ultrasound imaging (CT or MRI if necessary) are performed every 3 to 6 months to detect HCC early. 4 During the treatment of Tenofovir, serum creatinine, blood phosphorus and blood lactic acid should be tested once a month for 3 consecutive tests. After the disease is improved, it can be tested every 3 months; if the patient has bone pain, joint muscle soreness, etc. Timely, relevant indicators such as bone density should be tested at any time.
(2) Follow-up after Tenofovir withdrawal: Tenofovir antiviral therapy should be discontinued carefully, and prolonged Tenofovir treatment can reduce recurrence. ALT, HBsAg, HBeAg, anti-HBe and HBV DNA should be detected at least once every 1-2 months after discontinuation of the drug, and once every 3 to 6 months, at least 12 months. If there is a change in the condition during follow-up, the follow-up interval should be shortened.